Device Trial Radar · NCT05822232
FreeStyle Libre 2 Discharge Trial
Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 17, 2022
Primary completion
Apr 30, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Palo Alto Medical FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott Diabetes Care; Emory University
- First posted
- Apr 20, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the benefits of using aa Continuous Glucose Monitoring (CGM) system in patients with diabetes following discharge from the hospital. The main question it aims to answer is: • If the use of CGM with alarms is safe and effective for managing low and/or high blood sugars when compared with performing finger sticks several times per day Participants will wear one or two FreeStyle Libre CGM sensors for 12-14 days three times over a 12-week (3 month) period. This means that they will have the one to two sensors inserted under their skin. They will be asked to come to the study site four times and complete two phone calls with research staff over the 12-week period. Researchers will compare the LibreView CGM group to the Standard of Care group to see if the use of continuous glucose monitoring (CGM) reduces risk of low blood sugar in patients with type 2 diabetes (T2D) after hospital discharge when compared with the current standard method.
Conditions
- Diabetes Mellitus, Type 2
- Hypoglycemia
Interventions
FreeStyle Libre 2 CGMDevice
FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
FreeStyle Libre Pro blinded CGMDevice
FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
FreeStyle Precision Neo blood glucose meterDevice
FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EndpointTime frame: 2 weeks
5 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Palo Alto Medical Foundation Research Institute
Palo Alto, California · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.